Aurobindo Pharma Ltd

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorization from the European Commission for Dazublys', its trastuzumab biosimilar version. Earlier in April 2025, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dazublys', recommending its marketing authorization. This is CuraTeQ's third biosimilar to be approved by EMA after the approval of Dyrupeg' in April 2025 and Zefylti' in February 2025, and the fourth overall in the EU, alongside the approval of Bevqolva' by the UK's MHRA in December 2024.Powered by Capital Market - Live

Aurobindo Pharma announced that its wholly owned step-down subsidiary, Lyfius Pharma has restarted the production at its Penicillin-G manufacturing facility, at Kakinada, Andhra Pradesh with immediate effect, after receiving the consent to operate from Andhra Pradesh Pollution Control Board on 29 June 2025. Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1122.7, up 0.22% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25402.2. The Sensex is at 83287.99, up 0.64%. Aurobindo Pharma Ltd has slipped around 5.75% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 0.94% in last one month and is currently quoting at 21804.8, down 0.35% on the day. The volume in the stock stood at 7.57 lakh shares today, compared to the daily average of 12.2 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1121.7, up 0.22% on the day. Aurobindo Pharma Ltd is down 5.52% in last one year as compared to a 5.65% jump in NIFTY and a 11.34% jump in the Nifty Pharma index.The PE of the stock is 37.57 based on TTM earnings ending March 25.Powered by Capital Market - Live

Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a 'biosimilar medicine'; this means that Dyrupeg is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the area of the regulatory agency. Dyrupeg is intended for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ's third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025. Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company's consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24. The scrip advanced 0.84% to currently trade at Rs 1113.25 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma announced that CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg', its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg' received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ's third biosimilar to be approved by MHRA after the approval of Bevqolva' in December 2024 and Zefylti' in May 2025. Powered by Capital Market - Live

Aurobindo Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 1109.7, down 3.12% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.42% on the day, quoting at 24841.65. The Sensex is at 81516.35, down 0.34%.Aurobindo Pharma Ltd has lost around 7.98% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 0.21% in last one month and is currently quoting at 22039.45, down 1.57% on the day. The volume in the stock stood at 7.72 lakh shares today, compared to the daily average of 10.99 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1118, down 2.71% on the day. Aurobindo Pharma Ltd tumbled 10.7% in last one year as compared to a 5.45% rally in NIFTY and a 9.42% spurt in the Nifty Pharma index.The PE of the stock is 38.37 based on TTM earnings ending March 25.Powered by Capital Market - Live

Aurobindo Pharma USA Inc. has incorporated a new wholly owned subsidiary in USA by the name of CRESEDEMO PHARMA LLC in order to expand the Pharmaceutical Products business in USA. Powered by Capital Market - Live

The purpose of incorporating this new entity is to expand the company's pharmaceutical products business in USA. The company has subscribed to a share capital of $10,000 divided into 10,000 shares with a nominal value of $1 each. Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company's consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24. The scrip declined 0.38% to end at Rs 1,150.65 on the BSE.Powered by Capital Market - Live

The purpose of the incorporation of this wholly owned subsidiary is to expand the Biopharma Products business in Europe. The company has subscribed to an initial share capital of Euro 10,000, divided into 10,000 shares with a nominal value of Euro 1.00 each. Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company's consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24. The scrip declined 3.61% to end at Rs 1,147.95 on the BSE.Powered by Capital Market - Live

Securities in F&O Ban: Chambal Fertilisers & Chemicals, Hindustan Copper, Manappuram Finance, RBL Bank and Titagarh Rail Systems are banned from F&O trading on 27 May 2025. Upcoming Results: Life Insurance Corporation of India, Bharat Dynamics, Bosch, DCX Systems, Dynamatic Technologies, EID Parry India, Entero Healthcare Solutions, Esab India, Gujarat Fluorochemicals, Gateway Distriparks, Goodyear India, Hindustan Copper, ITI, JK Lakshmi Cement, Medplus Health Services, Minda Corporation, Info Edge (India), NMDC, V2 Retail will declare their results later today. Stocks to Watch: Aurobindo Pharma's consolidated net profit fell 0.6% to Rs 903.47 crore despite of 11.9% increase in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24. Akums Drugs & Pharmaceuticals reported consolidated net profit of Rs 147.62 crore in Q4 FY25 as compared with net loss of Rs 41.32 crore in Q4 FY24. Net sales jumped 11.8% YoY to Rs 1,055.55 crore in Q4 FY25. Vadilal Industries' consolidated net profit declined 20.4% to Rs 22 crore in Q4 FY25 from Rs 27.64 crore in Q4 FY24. Net sales rose 9.2% YoY to Rs 274.47 crore during the quarter ended 31st March 2025. Orchid Pharma reported a 32.4% decline in consolidated net profit to Rs 22.29 crore in Q4 FY25 as compared with Rs 32.96 crore in Q4 FY24. Net sales increased 9.4% YoY to Rs 237.48 crore in Q4 FY25. Awfis Space Solutions' consolidated net profit soared 713.8% to Rs 11.23 crore on 46.2% increase in net sales to Rs 339.69 crore in Q4 FY25 over Q4 FY24. Olectra Greentech reported a 53.2% increase in consolidated net profit to Rs 21 crore on 55.4% rise in net sales to Rs 448.92 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live